Merit CRO

Merit CRO

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

MERIT CRO is a private, revenue-generating services company founded in 2003, headquartered in Madison, Wisconsin, USA. It has established itself as a specialized endpoint expert, providing critical imaging and assessment services for global clinical trials, with a proven track record serving 13 of the top 20 global pharma companies. The company's growth is underscored by its inclusion on the Inc. 5000 list for eight consecutive years and its strategic acquisition of OSOD to expand into preclinical research. MERIT's business model is built on deep therapeutic area expertise, a standardized operational approach, and its proprietary EXCELSIOR™ software platform.

OphthalmologyOncologyRespiratoryCardiology

Technology Platform

EXCELSIOR™, a comprehensive, cloud-based software platform providing a suite of advanced endpoint analysis tools, real-time sponsor access, and standardized workflows for site certification, data management, reader monitoring, and output.

Funding History

1
SeedUndisclosed

Opportunities

Growth is driven by increasing outsourcing of specialized endpoint assessment, the complexity of novel therapies requiring advanced imaging, and global trial expansion.
The acquisition of OSOD allows a seamless preclinical-to-clinical service offering, capturing more client spend.

Risk Factors

Business is tied to biopharma R&D spending cycles.
Faces competition from other specialty CROs and large full-service CROs.
Operational reputation risk is high, as data quality failures on a key trial could be damaging.
Relies on maintaining deep therapeutic area expertise.

Competitive Landscape

MERIT competes with other specialized imaging and endpoint CROs (e.g., BioClinica, ICON's Medical Imaging division, Calyx) and the central lab divisions of large, full-service CROs. Its differentiators are its focused therapeutic expertise, proprietary EXCELSIOR™ platform, and integrated preclinical/clinical services.